Recently added

DSpace/Manakin Repository

UMC Repository: Recent submissions

Now showing items 3761-3780 of 40729

Challenges in Advanced Therapy Medicinal Product Development: A Survey among Companies in Europe

ten Ham, Renske M.T.; Hoekman, Jarno; Hövels, Anke M.; Broekmans, Andre W.; Leufkens, Hubert G.M.; Klungel, Olaf H. (Cell Press, 2018-12-14)

Advanced therapy medicinal products (ATMPs) hold promise as treatments for previously untreatable and high-burden diseases. Expectations are high and active company pipelines are observed, yet only 10 market authorizations ...
Human herpesvirus 6 viremia affects T-cell reconstitution after allogeneic hematopoietic stem cell transplantation

de Koning, Coco; Admiraal, Rick; Nierkens, Stefan; Boelens, Jaap Jan (The American Society of Hematology, 2018-02-27)

Human herpesvirus 6 (HHV6) viremia is a common cause of morbidity following allogeneic hematopoietic cell transplantation (HCT).Wepreviously associated T-cell reconstitution with HHV6 viremia. Here, we investigated whether ...
"Immune" Thrombocytopenia as Key Feature of a Novel ADA2 Deficiency Variant: Implication on Differential Diagnostics of ITP in Children

Sundin, Mikael; Marits, Per; Nierkens, Stefan; Kolios, Antonios G A; Nilsson, Jakob (Lippincott Williams & Wilkins, 2019-03)

Thrombocytopenia presenting during early childhood is most commonly diagnosed as immune/idiopathic thrombocytopenic purpura (ITP), where the antibody-mediated destruction of thrombocytes is often transient. If treatment ...
Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution

Kellner, Joshua N; Delemarre, Eveline M; Yvon, Eric; Nierkens, Stefan; Boelens, Jaap J; McNiece, Ian; Olson, Amanda; Nieto, Yago; Ciurea, Stefan; Popat, Uday; Ahmed, Sairah; Champlin, Richard; Ramos, Jennifer; Nishimoto, Mitsutaka; Ma, Hongbing; Ke, Zeng; Thall, Peter; Khoury, Joseph D; Negrin, Robert; Andersson, Borje; Parmar, Simrit (Impact Journals, 2018-11-01)

Incubation of umbilical cord blood (UCB) derived regulatory T-cells (Tregs) with fucosyltransferase enzyme improves their ability to home to the target tissue to prevent graft vs. host disease (GVHD). We report results of ...
Quantification of neutralizing anti-drug antibodies and their neutralizing capacity using competitive displacement and tandem mass spectrometry: Infliximab as proof of principle

El Amrani, Mohsin; Göbel, Camiel; Egas, Annelies C; Nierkens, Stefan; Hack, C Erik; Huitema, Alwin D R; van Maarseveen, Erik M (Elsevier, 2019-04)

Background: The development of anti-drug antibodies (ADA) in patients treated with therapeutic proteins can result in treatment failure. The clinically most relevant fraction of these antibodies are the neutralizing anti-drug ...
Samenvatting modulaire herziening Richtlijn Constitutioneel eczeem 2019

Hofhuis, M.F.; van der Schoot, L.S.; Le, T.M.; de Bruin-Weller, M.S. (DCHG Partners in Mediscne Communicatie, 2020)
Position Paper ETFAD: Behandeling constitutioneel eczeem rondom zwangerschap

de Bruin-Weller, M.S.; van Beek, D.; Schuttelaar, M.L.A. (DCHG Partners in Mediscne Communicatie, 2020)
Constitutioneel eczeem - Tioguanine voor de behandeling van (constitutioneel) eczeem

Garritsen, F.M.; de Bruin-Weller, M.S. (DCHG Partners in Mediscne Communicatie, 2019)

Azathioprine (AZA) is commonly used in the treatment of atopic dermatitis (AD), but high discontinuation rates due to side effects and ineffectiveness are reported. Thioguanine reduces generation of potentially toxic ...
Epidemiology of atopic dermatitis in adults: Results from an international survey

Barbarot, S; Auziere, S; Gadkari, A; Girolomoni, G; Puig, L; Simpson, E L; Margolis, D J; de Bruin-Weller, M; Eckert, L (Wiley-Blackwell, 2018-06)

BACKGROUND: There are gaps in our knowledge of the prevalence of adult atopic dermatitis (AD). OBJECTIVE: To estimate the prevalence of AD in adults and by disease severity. METHODS: This international, cross-sectional, ...
Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17 levels?: reply from the authors

de Bruin-Weller, M; Graham, N M H; Pirozzi, G; Shumel, B (Wiley-Blackwell, 2018-05)
COURRENT PINIONDupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?

van der Schaft, Jorien; Thijs, Judith L; de Bruin-Weller, Marjolein S; Balak, Deepak M W (Lippincott Williams & Wilkins, 2019-08)

PURPOSE OF REVIEW: The IL-4/13 antagonist dupilumab was approved in 2017 as the first biologic for atopic dermatitis. Here, we comprehensively review compelling new data regarding dupilumab published following the approval. ...
European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period

Vestergaard, C; Wollenberg, A; Barbarot, S; Christen-Zaech, S; Deleuran, M; Spuls, P; Flohr, C; Trzeciak, M; von Kobyletzki, L; Seneschal, J; Paul, C; Bieber, T; Werfel, T; Fölster-Holst, R; Darsow, U; Gieler, U; Svensson, Å; Cork, M; Stalder, J-F; De Raeve, L; Kunz, B; Simon, D; Chernyshov, P; Hijnen, D; Gelmetti, C; Ring, J; Taieb, A; de Bruin-Weller, M; Thyssen, J P (Wiley-Blackwell, 2019-09)

Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, including a large number of adults of reproductive age. Several guidelines for the treatment of AD exist, yet specific ...
Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis

Beck, Lisa A; Thaçi, Diamant; Deleuran, Mette; Blauvelt, Andrew; Bissonnette, Robert; de Bruin-Weller, Marjolein; Hide, Michihiro; Sher, Lawrence; Hussain, Iftikhar; Chen, Zhen; Khokhar, Faisal A; Beazley, Bethany; Ruddy, Marcella; Patel, Naimish; Graham, Neil M H; Ardeleanu, Marius; Shumel, Brad (Adis, 2020-08)

Background: Management of moderate-to-severe atopic dermatitis (AD) commonly requires long-term treatment. Objective: The aim of this study was to report the safety and efficacy of dupilumab treatment for up to 3 years in ...
Onderzoek naar effect van ondervoeding op werking van geneesmiddelen: Vasten kan medicijn minder effectief en veilig maken

Lammers, Laureen A; Achterbergh, Roos; Romijn, Hans; Mathot, Ron A. A. (Kon. Ned. Mij. ter Bevordering der Pharmacie (KNMP), 2019-03-22)
Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion

Thyssen, J P; de Bruin-Weller, M S; Paller, A S; Leshem, Y A; Vestergaard, C; Deleuran, M; Drucker, A M; Foelster-Holst, R; Traidl-Hoffmann, C; Eyerich, K; Taieb, A; Su, J C; Bieber, T; Cork, M J; Eichenfield, L F; Guttman-Yassky, E; Wollenberg, A (Wiley-Blackwell, 2019-07)

BACKGROUND: Conjunctivitis is common in patients with atopic dermatitis (AD) in general and a commonly reported adverse event in AD clinical trials with dupilumab. OBJECTIVE: To survey opinions and experience about ...
Towards personalized treatment in atopic dermatitis

van der Schaft, Jorien; Thijs, Judith L; Garritsen, Floor M; Balak, D; de Bruin-Weller, Marjolein S (Informa Healthcare, 2019-05)

INTRODUCTION: For many years, oral immunosuppressive drugs such as cyclosporine A, azathioprine, mycophenolic acid, and methotrexate were the only treatment options, in addition to topical treatment, in patients with severe ...
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ)

de Bruin-Weller, M; Thaçi, D; Smith, C H; Reich, K; Cork, M J; Radin, A; Zhang, Q; Akinlade, B; Gadkari, A; Eckert, L; Hultsch, T; Chen, Z; Pirozzi, G; Graham, N M H; Shumel, B (Wiley-Blackwell, 2018-05)

Background: Atopic dermatitis is a chronic inflammatory skin disease that may require systemic therapy. Ciclosporin A (CsA) is a widely used, potent immunosuppressant but it is not effective in all patients with atopic ...
Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment

Wollenberg, Andreas; Ariens, Lieneke; Thurau, Stephan; van Luijk, Chantal; Seegräber, Marlene; de Bruin-Weller, Marjolein (2018-09-01)
Conjunctivitis in dupilumab clinical trials

Akinlade, B; Guttman-Yassky, E; de Bruin-Weller, M; Simpson, E L; Blauvelt, A; Cork, M J; Prens, E; Asbell, P; Akpek, E; Corren, J; Bachert, C; Hirano, I; Weyne, J; Korotzer, A; Chen, Z; Hultsch, T; Zhu, X; Davis, J D; Mannent, L; Hamilton, J D; Teper, A; Staudinger, H; Rizova, E; Pirozzi, G; Graham, N M H; Shumel, B; Ardeleanu, M; Wollenberg, A (Wiley-Blackwell, 2019-09)

BACKGROUND: Dupilumab blocks the shared receptor component for interleukin (IL)-4 and IL-13. It is approved in the U.S.A. for patients aged ≥ 12 years with moderate-to-severe atopic dermatitis (AD) uncontrolled by topical ...
Recurrence of conjunctival goblet cells after discontinuation of dupilumab in a patient with dupilumab-related conjunctivitis

Voorberg, A N; den Dunnen, W F A; Wijdh, R H J; de Bruin-Weller, M S; Schuttelaar, M L A (Wiley-Blackwell, 2020-02-01)

Now showing items 3761-3780 of 40729